



New Developments In Prevention And Treatment Of Pediatric Infectious Diseases

Ahmed Abdelsamie Fadl^{1*}, Jaber Abdullah Mudawi², Abdulhadi Mohammed Alqahtani³, Futoon jomman A Alomari⁴, Fatema hasan janahi⁵, Azahar Essa Asaleem⁶, Fatimah Baqer Alfaraj⁷, Farah Abdulelah A Al Sheif⁸, Bayan Abduljalil Mansoor Zabeel⁹, Kheder Mabrook ALGhamdi¹⁰, Abdullah Mohammed Bin Hussain¹¹, Hanan Ziaullah Farooqi¹², Salwa mabrouk Alharbi¹³, Nebras Omar Jaber Bedair¹⁴

^{1*}*Pediatric senior registrar at Doctor Samir Abbas Hospital, Department of pediatrics, Alazhar University hospitals, Cairo. Email: Dr_fadl844@yahoo.com*

²*Al-manhal PHC in Abha health sector, KSA. Email: Jabermodawi@gmail.com*

³*KING ABDULAZIZ HOSP, MAKKAH, KSA. Email: amq2524@gmail.com*

⁴*King Abdulaziz Hospital, Makkah, KSA. Email: Futoon_alomari@hotmail.com*

⁵*Working in royal Bahrain hospital. Email: Fatemaa.janahi@gmail.com*

⁶*Omran General Hospital, AlAhsa, Saudi Arabia. Email: Azhaary91@gmail.com*

⁷*Medical university of Lodz. Email: Fofow580I@hotmail.com*

⁸*Intern, Imam Abdulrahman Bin Faisal University (Dammam, Saudi Arabia.*

⁹*Almalaki Specialist Hospital, Riffa- Bahrain. Email: dr.bayan.abduljalil@gmail.com*

¹⁰*King Khalid University, KSA. Email: Khederghamdi@hotmail.com*

¹¹*Intern, Department of medical collage at Shaqra university, Kingdom of Saudi Arabia. Email: abbmoo22@gmail.com*

¹²*Al Maarefa university (Riyadh, KSA. Email: Hananfarooqi@gmail.com*

¹³*King Abdulaziz University, KSA. Email: Salwaalharbi33@gmail.com*

¹⁴*King salman bin abdulaziz medical city Madinah, KSA. Email: wnosaw@yahoo.com*

***Corresponding Author:** Ahmed Abdelsamie Fadl

Pediatric senior registrar at Doctor Samir Abbas Hospital, Department of pediatrics, Alazhar University hospitals, Cairo. Email: Dr_fadl844@yahoo.com

Abstract

Both adults and children are regularly afflicted by infectious illnesses. We now have a better understanding of their epidemiology, pathophysiology, prevention, and treatment because of new diagnostic techniques. Recently, emerging infections have surfaced, prompting health officials to issue warnings. Furthermore, novel anti-microbial therapies have been identified; however, because of the potential for adverse effects on antimicrobial resistance, it is critical to understand when to utilize these therapies in order to prevent overuse and misuse. In addition, new vaccinations have entered the market, and it is crucial that medical professionals understand how they may affect public health. Also the use of prebiotics and probiotics has emerged now as a preventive measure for pediatric infectious diseases.

CC License
CC-BY-NC-SA 4.0

Keywords: Prevention, Treatment, Pediatric infectious diseases, Prebiotics, Probiotics

Introduction

Pediatric infectious diseases refer to illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that affect children. These diseases can range from common infections like the flu or strep throat to more serious conditions like pneumonia or meningitis. Children are particularly vulnerable to infectious diseases due to their developing immune systems and frequent exposure to germs in school and daycare settings [1]. Children's acute illnesses are most often caused by infections. These are often respiratory illnesses, which reach their climax when the child begins daycare or school. Many families who care for children experience severe pain, worry, lost work, and stress due to these disorders, even though the majority of them have benign courses. By adhering to best evidence-based practice and fostering a positive doctor-patient (and parent) connection, it is possible to minimize the number of office visits, unnecessary pharmaceutical prescriptions, and sometimes questionable home cures [2]. Infection-related morbidity and mortality have significantly decreased in developed nations, and infectious disease-related fatalities are now rare. Serious infections still happen, however, such as meningococcal septicemia, meningitis, and multidrug-resistant bacteria. Some diseases have even returned, such as TB and *Staphylococcus aureus* which are secreted by PVL toxins, which calls for prompt diagnosis and treatment. Tropical illnesses are becoming more common worldwide as air travel increases. Furthermore, epidemics—like SARS and H1N1 influenza—may spread rapidly, with youngsters and the elderly being the most susceptible [2].

The diseases known as infectious diseases are those brought on by bacteria. It's critical to understand that not all pathogens, including bacteria, viruses, fungi, and parasites, are harmful. As a matter of fact, the skin, eyelashes, nose, mouth, and stomach are all often home to a wide variety of bacteria. These bacteria are referred to as normal occupants and are known as normal flora. These common plants are beneficial to humans! Foods are broken down by the bacteria in our intestines to produce vitamin K, which is a necessary vitamin for everyone. Our natural skin and oral bacteria keep us safe from infection by limiting the growth of potentially dangerous bacteria and fungus. Antibiotics and some diseases have the potential to disturb the usual balance of microorganisms. Body surfaces are often damaged by viral diseases, which also prepare the body for bacterial invasion.

Many times, there are germs in the intestines, on the nose, or in the throat, but no sickness is visible. This is known as bacterial carriage, and the individual who carries the bacterium is referred to as a carrier. Although the carrier is healthy, there is a chance that the carrier may infect someone else. Numerous germs that are transported have the ability to infect and sicken [3].

Taking care of an ill child in an emergency might be difficult. Infectious diseases in children may present with a variety of symptoms, making a precise diagnosis challenging. To avoid a potentially fatal consequence, pediatric practitioners must identify the infectious condition that may be causing the child's symptoms as soon as possible. The practitioner should start isolation measures right once they detect an infectious condition. Interventions to keep the ill child's airway, oxygenation, circulation, and hydration sufficient should be started if necessary [4].

Furthermore, pediatric infectious disease knowledge, prevention, diagnosis, and treatment have advanced significantly during the last decades. Vaccines have made it feasible to eradicate diseases; good hygiene practices have drastically decreased the transmission of infections in hospitals; and antibiotics have made it possible to treat illnesses for which there was previously no hope. We have been able to dispel certain misunderstandings about commonly used medicines and unequivocally demonstrate the effectiveness of others thanks to evidence-based medicine. In the twenty-first century, the growth of knowledge and technology has been tremendous [5]. New developments in the prevention and treatment of infectious diseases have been seen greatly in the last years. The aim of this review is to highlight the new developments in the prevention strategies and treatments for the pediatric infectious diseases.

Prevention Strategies for Pediatric Infectious Diseases

In recent years, there have been several significant developments in the prevention and treatment of pediatric infectious diseases. These developments have focused on various strategies to reduce the incidence and severity of infections in children. One such strategy is the widespread implementation of vaccinations. Vaccinations have proven to be highly effective in preventing many childhood infectious diseases, such as measles, mumps, rubella, polio, and whooping cough. Additionally, research has shown that vaccines not only protect vaccinated

individuals but also contribute to herd immunity, reducing the overall transmission of infectious diseases within a community and decreasing the risk of outbreaks [6, 7].

New developments in preventive measures for pediatric infectious diseases include the development of new vaccines, improvements in vaccine delivery methods, and increased efforts to promote vaccination coverage. The newly developed vaccines target a broader range of infectious diseases, providing children with increased protection. Additionally, there have been advancements in the development of combination vaccines that offer protection against multiple diseases with a single injection, reducing the number of injections required for complete protection [8]. Furthermore, there have been advances in vaccine delivery methods, such as the development of needle-free delivery systems or oral vaccines, which are more convenient and less painful for children. Another important development in preventive measures is the implementation of public health initiatives that aim to increase vaccination coverage. These initiatives include the Expanded Program on Immunization and other national immunization programs that aim to ensure all children have access to vaccines and achieve high immunization rates [9]. There has been also an increased evidence for the use of prebiotics and probiotics in the prevention and treatment of pediatric infectious diseases [10]. Numerous researches have shown how probiotic usage shifted from traditional medicine to more scientifically supported practices. There is evidence to support the use of certain probiotics as a preventative measure against gastrointestinal disorders and as an adjuvant therapy for acute viral gastroenteritis. Prebiotics and probiotics have additional functions in the prevention of respiratory infections as well as general infectious disorders. Reputable randomized-controlled studies have yielded data that bolster probiotics' potential as a treatment for necrotizing enterocolitis in premature newborns. Because of their ability to stimulate the host's immune system, bioactive substances have been suggested for use in therapeutic settings. Furthermore, biotherapeutic items like postbiotics—roughly characterized as substances formed during a fermentation process that enhances health and wellbeing—support intestinal barrier integrity without endangering children's health in a significant way [10, 11].

Probiotics are living bacteria that provide the host health benefits when given in sufficient doses. Prebiotics, on the other hand, are indigestible dietary elements that specifically stimulate the development and/or activity of a single or small group of bacteria in the colon, having a positive effect on the host. Probiotics and prebiotics together make up synbiotics. Probiotics are recommended primarily because of their capacity to alter microbial populations, favoring the development and survival of beneficial bacteria over that of harmful bacteria. Additionally, they regulate and support intestinal barrier function, proliferation, and differentiation of epithelial cells *in vitro*, as well as immune-modulatory activities [10]. Human milk oligosaccharides, which are present in human breast milk, exhibit the prebiotic properties that have been effectively mimicked by commercialized prebiotics. They are used to specifically encourage commensal bacterial colonization, growth, survival, and function [12]. They may also influence immune system activity. Owing to structural variations from human milk oligosaccharides, they may not be able to provide additional health advantages in addition to their prebiotic role [10]. In an observational study conducted recently on 771 infants, the group that received a follow-up formula supplemented with synbiotics had significantly fewer infectious diseases overall than the control group [13]. However, when specific infectious diseases were examined, the difference was only statistically significant for the frequency of gastrointestinal infections [14]. Another study showed that the probiotic group saw a 30% decrease in the overall number of infectious diseases when compared to the control group. Specifically examining the effect of prebiotics on fever episodes during the first year of life, van Stuijvenberg et al. were unable to show a decrease in the intervention group [15]. A recent experiment showed that the synbiotic group got less antibiotics over the intervention period (0–6 months) than the placebo group. On the other hand, during the follow-up period (6–24 months), the investigators did not notice any variations in the usage of antibiotics [16]. It needs to be seen whether subsequent research can validate the potentially positive benefits of probiotics toward general infectious diseases, or if these effects may be linked to a decrease of particular infectious diseases. Also another study done this year reviewed prevention and therapeutic role for the probiotics and prebiotics; the review demonstrated that planktonic probiotics may be supplied in formulations including many bacterial strains or as a single strain. Numerous randomized controlled studies have examined how single-strain planktonic probiotics affect the frequency of necrotizing enterocolitis [17]. Prebiotics are substrates that gut microorganisms use to improve the host's health. Among them are key metabolic substrates that are present in food, such tryptophan, which bacteria may break down into compounds that have distinctive characteristics. It has long been recognized that breast milk protects against necrotizing enterocolitis. It may help regulate TLR-4 signaling in the developing gut and includes protective maternal immunoglobulin A. According to more recent studies, breast milk given to a preterm baby produces short chain fatty acids, which have an anti-inflammatory impact on immature enterocytes [17].

Innovations in the Treatment of Pediatric Infectious Diseases

Traditional treatment methods for pediatric infectious diseases often involve the use of antibiotics or antiviral medications, depending on the specific infection. However, overuse and misuse of these medications have led to the emergence of antibiotic-resistant strains of bacteria, posing a significant challenge in the treatment of infectious diseases. To address this issue, new developments in treatment methods have emerged, focusing on alternative approaches and personalized medicine. One area of new development in the treatment of pediatric infectious diseases is the management of infections in children with rheumatic diseases who are undergoing immunosuppressive treatment [18, 19].

In recent years, there have been several innovations in the treatment of pediatric infectious diseases that aim to improve outcomes and reduce the burden of these diseases on children. Innovative approaches in the treatment of pediatric infectious diseases include the use of immunotherapy, which harnesses the body's immune system to fight off infections more effectively. This can involve the use of monoclonal antibodies or other immune-modulating therapies to enhance the body's natural defenses against infectious agents [20]. Another innovation is the development of novel antiviral drugs that specifically target the replication process of viruses, providing more effective treatment options. Additionally, there are ongoing research efforts to develop new antimicrobial agents that can combat antibiotic-resistant bacteria and novel antifungal medications for the treatment of fungal infections in children. Furthermore, advancements in diagnostic techniques have enabled faster and more accurate identification of infectious agents, allowing for targeted treatment strategies. These new developments in the prevention and treatment of pediatric infectious diseases address several key challenges. They aim to overcome antibiotic resistance, improve the efficacy and specificity of treatment options, and enhance the overall management of infectious diseases in pediatric patients [21-23].

Challenges and Solutions in Implementing New Practices

While new developments in the prevention and treatment of pediatric infectious diseases offer promising solutions, there are challenges in implementing these practices. These challenges include the cost and accessibility of these new therapies, as well as the need for further research and clinical trials to establish their safety and efficacy in pediatric populations. Additionally, there is a need for continued education and awareness among healthcare professionals to ensure proper utilization of these new interventions. In order to overcome these challenges, collaboration between researchers, healthcare providers, and regulatory bodies is essential. In conclusion, there have been significant advancements in the prevention and treatment of pediatric infectious diseases. These advancements include the use of immunotherapy and novel antiviral drugs, which have shown positive outcomes in case studies. However, there are challenges in implementing these new practices due to cost, accessibility, and the need for further research [22, 24].

Future Trends in Pediatric Infective Disease Prevention and Treatment

In the future, several trends can be expected in the prevention and treatment of pediatric infectious diseases. These may include the development of more targeted and personalized therapies, advancements in vaccine technology, and the use of artificial intelligence and big data analytics for improved disease surveillance and outbreak prediction. Overall, the field of pediatric infectious diseases is constantly evolving, with ongoing research and technological advancements. With the rapid advancement of technology and scientific research, new developments in the prevention and treatment of pediatric infectious diseases are constantly emerging. Some potential future trends in the prevention and treatment of pediatric infectious diseases include: the use of nanotechnology for targeted drug delivery, the development of vaccines with broader coverage against multiple pathogens, and the integration of telemedicine and remote monitoring systems to improve access to healthcare in underserved areas. Additionally, there is a growing focus on the use of probiotics and prebiotics for immune support and gut health, as well as the exploration of new diagnostic tools and techniques, such as point-of-care testing and rapid genomic sequencing, for early detection and identification of infectious pathogens [25]. Furthermore, strategies to address antimicrobial resistance and promote responsible antibiotic use will continue to be a key focus in the prevention and treatment of pediatric infectious diseases. Incorporating research and development in the field of pediatric infectious diseases, alongside effective collaboration between healthcare providers, researchers, regulatory bodies, and policymakers is crucial in order to effectively address the challenges posed by pediatric infectious diseases and ensure that new developments in prevention and treatment translate into meaningful improvements in child health and well-being. In the future, we can expect to see advancements in the prevention and treatment of pediatric infectious diseases. For example, the development

of innovative therapies targeted towards specific pathogens and personalized to individual patients holds promise for more effective treatment outcomes.

Conclusion

New developments in the prevention and treatment of pediatric infectious diseases have had a significant impact on pediatric healthcare. These advancements have provided better treatment options, improved outcomes, and reduced the burden of infectious diseases on children. Additionally, they have allowed for the management of chronic illnesses such as HIV in children, leading to longer and more normalized lives. In conclusion, there have been significant advancements in the prevention and treatment of pediatric infectious diseases. These advancements have resulted in decreased morbidity and mortality rates, improved quality of life for children, and reduced healthcare costs.

References

1. Overview of Infectious Diseases - HealthyChildren.org. (2015). <https://healthychildren.org/English/health-issues/conditions/infections/Pages/Overview-of-Infectious-Diseases.aspx>
2. Musmar, S., & Fitian, H. (2016). Infectious Diseases of Children. *Family Medicine: Principles and Practice*, 241–253. https://doi.org/10.1007/978-3-319-04414-9_18
3. Overview of Infectious Diseases. (n.d.). HealthyChildren.org. <https://healthychildren.org/English/health-issues/conditions/infections/Pages/Overview-of-Infectious-Diseases.aspx>
4. Normandin P. A. (2015). Pediatric infectious diseases. *Journal of emergency nursing*, 41(2), 160–161. <https://doi.org/10.1016/j.jen.2014.12.008>
5. Van Rostenberghe H. (2014). Pediatric infectious diseases: getting research evidence into practice and generation of new evidence. *Frontiers in pediatrics*, 2, 138. <https://doi.org/10.3389/fped.2014.00138>
6. Greenwood B. (2014). The contribution of vaccination to global health: past, present and future. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences*, 369(1645), 20130433. <https://doi.org/10.1098/rstb.2013.0433>
7. Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: from basic principles to new developments. *Nature reviews. Immunology*, 21(2), 83–100. <https://doi.org/10.1038/s41577-020-00479-7>
8. Nandi, A., & Shet, A. (2020). Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination. *Human vaccines & immunotherapeutics*, 16(8), 1900–1904. <https://doi.org/10.1080/21645515.2019.1708669>
9. Truong, L. T. T., Thai, T. T., Nguyen, T. V., Nguyen, T. Q., Le, T. A. T., Le, N. H., Pham, P. T. T., & Huynh, Q. N. H. (2023). Levels and Associated Factors of Clients' Satisfaction Toward Child Immunization at Grassroot Health Care Centers in Ho Chi Minh City, Vietnam. *Risk management and healthcare policy*, 16, 793–803. <https://doi.org/10.2147/RMHP.S400238>
10. Weichert, S., Schrotten, H., & Adam, R. (2012). The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. *The Pediatric infectious disease journal*, 31(8), 859–862. <https://doi.org/10.1097/INF.0b013e3182620e52>
11. Mantziari, A., Salminen, S., Szajewska, H., & Malagón-Rojas, J. N. (2020). Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases. *Microorganisms*, 8(10), 1510. <https://doi.org/10.3390/microorganisms8101510>
12. Roberfroid, M., Gibson, G. R., Hoyles, L., McCartney, A. L., Rastall, R., Rowland, I., Wolvers, D., Watzl, B., Szajewska, H., Stahl, B., Guarner, F., Respondek, F., Whelan, K., Coxam, V., Davicco, M. J., Léotoing, L., Wittrant, Y., Delzenne, N. M., Cani, P. D., Neyrinck, A. M., ... Meheust, A. (2010). Prebiotic effects: metabolic and health benefits. *The British journal of nutrition*, 104 Suppl 2, S1–S63. <https://doi.org/10.1017/S0007114510003363>
13. Picaud, J. C., Chapalain, V., Paineau, D., Zourabichvili, O., Bornet, F. R., & Duhamel, J. F. (2010). Incidence of infectious diseases in infants fed follow-on formula containing synbiotics: an observational study. *Acta paediatrica (Oslo, Norway: 1992)*, 99(11), 1695–1700. <https://doi.org/10.1111/j.1651-2227.2010.01896.x>
14. Maldonado, J., Cañabate, F., Sempere, L., Vela, F., Sánchez, A. R., Narbona, E., López-Huertas, E., Geerlings, A., Valero, A. D., Olivares, M., & Lara-Villoslada, F. (2012). Human milk probiotic *Lactobacillus fermentum* CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract

- infections in infants. *Journal of pediatric gastroenterology and nutrition*, 54(1), 55–61. <https://doi.org/10.1097/MPG.0b013e3182333f18>
15. van Stuijvenberg, M., Eisses, A. M., Grüber, C., Mosca, F., Arslanoglu, S., Chirico, G., Braegger, C. P., Riedler, J., Boehm, G., & Sauer, P. J. (2011). Do probiotics reduce the number of fever episodes in healthy children in their first year of life: a randomised controlled trial. *The British journal of nutrition*, 106(11), 1740–1748. <https://doi.org/10.1017/S0007114511004053>
 16. Kukkonen, K., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T., Tuure, T., & Kuitunen, M. (2008). Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. *Pediatrics*, 122(1), 8–12. <https://doi.org/10.1542/peds.2007-1192>
 17. Wala, S. J., Ragan, M. V., Sajankila, N., Volpe, S. G., Purayil, N., Dumbauld, Z., & Besner, G. E. (2023). Probiotics and novel probiotic delivery systems. *Seminars in pediatric surgery*, 32(3), 151307. <https://doi.org/10.1016/j.sempedsurg.2023.151307>
 18. Donà, D., Zingarella, S., Gastaldi, A., Lundin, R., Perilongo, G., Frigo, A. C., Hamdy, R. F., Zaoutis, T. E., Dalt, L. D., & Giaquinto, C. (2018). Effects of clinical pathway implementation on antibiotic prescriptions for pediatric community-acquired pneumonia. <https://scite.ai/reports/10.1371/journal.pone.0193581>
 19. Nagotkar, L., Shanbag, P., Mauskar, A., Zaki, S. A., & Kumar, C. A. (2011). Fulminant intracranial hypertension due to cryptococcal meningitis in a child with nephrotic syndrome. <https://scite.ai/reports/10.4103/0972-5229.84905>
 20. Seria, E., Tagliaferro, S. S., Cutajar, D., Galdies, R., & Felice, A. E. (2021). Immunoglobulin G in Platelet-Derived Wound Healing Factors. <https://scite.ai/reports/10.1155/2021/4762657>
 21. Caioni, G., Benedetti, E., Perugini, M., Amorena, M., & Merola, C. (2023). Personal Care Products as a Contributing Factor to Antimicrobial Resistance: Current State and Novel Approach to Investigation. <https://scite.ai/reports/10.3390/antibiotics12040724>
 22. Liu, B., Cao, B., Wang, C., Han, B., Sun, T., Miao, Y., Lu, Q., & Cui, F. (2022). Immunogenicity and Safety of Childhood Combination Vaccines: A Systematic Review and Meta-Analysis. <https://scite.ai/reports/10.3390/vaccines10030472>
 23. Queiroz, A. M. V., Oliveira, J. W. D. F., Moreno, C. J. G., Guérin, D. M. A., & Silva, M. S. (2021). VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases. <https://scite.ai/reports/10.3390/vaccines9030220>
 24. Yildirim-Toruner, C., Pooni, R., Goh, Y. I., Becker-Haimes, E. M., Dearing, J. W., Fernandez, M. E., Morgan, E. M., Parry, G., Burnham, J. M., Ardoin, S. P., Barbar-Smiley, F., Chang, J., Chiraseveenupund, P., Gaizo, V. D., Eakin, G., Johnson, L. G., Kimura, Y., Knight, A., Kohlheim, M., ... Scheven, E. V. (2022, February 7). Translating research into practice—implementation recommendations for pediatric rheumatology; Proceedings of the childhood arthritis and rheumatology research alliance 2020 implementation science retreat. <https://scite.ai/reports/10.1186/s12969-022-00665-y>
 25. Kamat, S., Kumari, M., & Jayabaskaran, C. (2021). Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2. *Journal of controlled release: official journal of the Controlled Release Society*, 338, 813–836. <https://doi.org/10.1016/j.jconrel.2021.08.046>